Search

Displaying results 4741 - 4750 of 5758 in total
  1. Drug

    Temsavir

    go.drugbank.com/drugs/DB14675
    Investigational

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  3. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and

  4. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  5. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.

  6. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  7. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Afri...

  8. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. Both hemolysis and thrombophilia are mediated primarily by the complement system. St...

    Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideCategories: P-glycoprotein inhibitors
  10. Drug

    Yersinia pestis 195/p antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15461
    Investigational

    Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).

    Synonyms: Yersinia pestis 195/p antigen (formaldehyde inactivated)